Genmab announced positive phase 3 results for Rina-S in platinum-resistant ovarian cancer and released encouraging Phase 2 data for petosemtamab in head and neck squamous cell carcinoma and metastatic colorectal cancer. Shares jumped over 12% on Oct. 26.
Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.
Large acquisitions and heavier R&D spending increase financial risk if new drugs fail to meet expectations or achieve meaningful commercial uptake.
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.14 | 53.07 | 13.01 |
Price/Book Value | 4.72 | 1.32 | 3.69 |
Price/Sales | 7.06 | 2.16 | 4.11 |
Price/Cash Flow | 28.71 | 12.06 | 10.36 |
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Quick Ratio | 2.44 | 0.54 | 4.31 |
Current Ratio | 2.46 | 1.14 | 4.59 |
Interest Coverage | 3.88 | 0.07 | 791.55 |
|
Metric
|
GMAB
|
4502
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 11.74% | 5.53% | 26.83% |
Return on Equity (Normalized) | 21.07% | 11.34% | 35.48% |
Return on Invested Capital (Normalized) | 14.75% | 7.74% | 33.21% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|J$D&blP | LOCK|%@g^% | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$%VJFN# | LOCK|$C<^& | $84B | |||
| Moderna Inc
MRNA
| LOCK|^$lmv^G | LOCK|%# | $83B | |||
| argenx SE ADR
ARGX
| LOCK|%>@QD^J | LOCK|z$< | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?#W!@$ | LOCK|TLn | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Y>$wq@% | LOCK|&#Mv | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!%zBXL!! | LOCK|<%w#w | $29B | |||
| Incyte Corp
INCY
| LOCK|&w#^dT! | LOCK|<! | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|t>j<X@p | LOCK|%M$ | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|@Gq?&?! | LOCK|JG& | $14B |
United States